ProCE Banner Activity

Multidisciplinary Perspectives on Practical Team-Based Application of Newly Available Agents in AML: A Video Training Guide

PDF
Download this PDF team training guide for a CCO video of expert recommendations on the optimal use of recently approved targeted therapies in patients with advanced AML, including therapy selection and adverse event management.

Released: July 19, 2018

Expiration: July 18, 2019

No longer available for credit.

Share

Faculty

Farhad Ravandi

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Elizabeth S. Kaled

Elizabeth S. Kaled, NP

Advanced Practice Nurse
Leukemia Department
The University of Texas MD Anderson Cancer Center
Houston, Texas

Deborah A. McCue

Deborah A. McCue, PharmD, BCOP

Manager, Clinical Pharmacy Services
Division of Pharmacy
The University of Texas MD Anderson Cancer Center
Houston, Texas

Supporters

Agios Pharmaceuticals

Celgene

Program Director Disclosure

Program Director

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Dr. Ravandi has reported that he has received consulting fees from Amgen, Astellas, Macrogenix, and Orsenix, and funds for contracted research from Amgen, Bristol-Myers Squibb, Macrogenix, Orsenix, and Seattle Genetics.

Faculty Disclosure

Primary Author

Elizabeth S. Kaled, NP

Advanced Practice Nurse
Leukemia Department
The University of Texas MD Anderson Cancer Center
Houston, Texas

Elizabeth Kaled, NP, has no real or apparent conflicts of interest to report.

Deborah A. McCue, PharmD, BCOP

Manager, Clinical Pharmacy Services
Division of Pharmacy
The University of Texas MD Anderson Cancer Center
Houston, Texas

Deborah A. McCue, PharmD, BCOP, has no real or apparent conflicts of interest to report.